3/28/2025

Rifapentine Tablets

Products Affected - Description

- Priftin oral tablet, Sanofi-Aventis, 150 mg, 24 count, NDC 00088-2102-24

Reason for the Shortage

- Sanofi did not provide a reason for the shortage.
- Sanofi is the sole supplier of rifapentine tablets.

Available Products

- There is insufficient supply for usual ordering

Estimated Resupply Dates

- Sanofi has Priftin 150 mg tablets in 24 count unit-dose packages on allocation.

Implications for Patient Care

- Rifapentine is an oral tablet used in combination with isoniazid to treat latent tuberculosis (TB) caused by Mycobacterium tuberculosis in patients aged 2 years and older. It is also used with one or more anti-tuberculosis drugs to treat active TB in patients 12 years and older.[1-2]

Alternative Agents & Management

- Guidelines for special populations and drug-resistant TB can be found in this recent update. Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline | American Journal of Respiratory and Critical Care Medicine.[3]
- Examples of alternate treatment regimens that do not include rifapentine are listed below.[3-5]
- For latent tuberculosis:
- 1. Daily rifampin for 4 months
- 2. Daily isoniazid plus rifampin for 3 months.
- 3. An alternative regimen consists of daily isoniazid for 6 to 9 months.
- For active tuberculosis:
- 1. Isoniazid, rifampin, pyrazinamide, and ethambutol. The specific duration and dosing interval depend on the selected regimen.

References

1. Rifapentine [package insert]. DailyMed. Published August 2021. Accessed March 27, 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3882444-18ca-4708-a51b-6c089664c10c
2. Rifapentine. Lexi-Drug Online. Wolters Kluwer Clinical Drug Information. Hudson, Ohio, USA. Accessed; Accessed March 27, 2025.
3. Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline | American Journal of Respiratory and Critical Care Medicine
4. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. MMWR Recomm Rep. 2020;69(RR-1):1-83. Accessed March 27, 2025. https://www.cdc.gov/mmwr/volumes/69/rr/rr6901a1.htm?s_cid=rr6901a1_w
5. Infectious Diseases Society of America. Treatment of Drug-Susceptible Tuberculosis. Accessed March 27, 2025. https://www.idsociety.org/practice-guideline/treatment-of-drug-susceptible-tb/

Updated

Updated March 28, 2025 by Michelle Wheeler, PharmD, Drug Information Specialist. Created February 25, 2025 by Leslie Jensen, PharmD, Drug Information Specialist. © 2025, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.